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Introduction 
Prognostic factors capable of predicting the neurological outcome of CA (cardiac 
arrest) patients following successful CPR (cardiopulmonary resuscitation) as early and 
accurately as possible are urgently needed, and many investigators have attempted to 
discover them[1,2]. However, none of the candidate prognostic predictors investigated thus 
far have predicted neurological outcome of CPR reliably enough to be used in clinical 
settings[3]. 
Among candidates of predictors, serum levels of biochemical markers can be 
measured easily and reproducibly with minor invasion to patients and are therefore expected 
to be applicable to clinical practice[4]. In particular, protein S-100B and neuron-specific 
enolase (NSE) are considered promising due to their superior reliability as predictors to other 
biochemical markers[5]. To improve the applicability of a biochemical marker in clinical 
practice, the following considerations are important: (1) a consistent definition of poor (good) 
prognosis should be used in assessing data from multiple studies; (2) the cutoff value for the 
biochemical marker should be determined so that the specificity in prediction of poor 
prognosis is 100%; and (3) the time point of blood sampling should be fixed in assessing time 
courses of change in blood levels of the biochemical marker. However, none of the reported 
studies meet the above requirements[1,5]. 
The objectives of the present study are to confirm the reliability of measurements 
of blood S-100B and NSE as prognostic predictors and to improve the applicability of these 
biochemical markers to clinical practice.  
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Methods 
Study design and patients 
This is a multicenter prospective observational study conducted between Oct 2006 
and Apr 2008 at three medical institutions in Chiba Prefecture, Japan. The present study was 
approved by the Institutional Review Board of the individual medical institutions. Informed 
consent for participation in the present study was obtained from family members or proxies 
of the patients, because all patients included in the present study had disorder of 
consciousness at enrollment (see below for exclusion criteria for the study). 
The subjects of the present study consisted of all patients aged 18 years or older 
who presented with either out-of-hospital or in-hospital CA and met the definition for 
"survived event"[6]. The term "survived event" in the out-of-hospital setting indicates 
sustained spontaneous circulation following the return of spontaneous circulation (ROSC) 
until admission and transfer of care to the medical staff at the receiving hospital. In the 
in-hospital setting, "survived event" means sustained circulation following ROSC for > 20 
minutes[6]. Patients with a terminal condition with known unfavorable cerebral performance 
as well as those responding to verbal commands after ROSC or with the Glasgow Coma 
Scale score of 9 or higher were excluded from the study (exclusion criteria). In addition, 
patients whose CPC were not evaluated due to death under analgesic sedation were 
eventually excluded from the study (exit criterion). 
Patient characteristics were extracted from emergency medical systems (EMS) 
reports and medical records of each receiving medical institution. The term definition 
conformed to “glossary of terms” as the Utstein templates indicates[6-8]. We also 
investigated whether initiation of Basic Life Support (BLS) within 5 minutes after CA 
influenced outcome. BLS for CA witnessed by emergency personnel and BLS for in-hospital 
CA were not defined as bystander CPR[7,8], and the present study, which included such cases, 
thus cannot investigate the relationship between presence or absence of bystander CPR and 
outcome. The time interval of 5 minutes employed was based on data reported by Pfeifer et 
al[9]. 
BLS and ACLS (Advanced Cardiovascular Life Support) were provided by the 
EMS or in-hospital resuscitation team according to the 2005 Guidelines[10]. Patients were 
admitted to the ICU, where standard medical management including invasive monitoring, 
haemodynamic support, mechanical ventilation, and analgesia sedation were provided. 
Application of therapeutic hypothermia (33±1°C) to prevent brain damage was considered for 
all patients, though this required consideration of various ethical and practical factors. In 
performing therapeutic hypothermia, the core body temperature was adjusted to and 
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maintained for 24 hours at 33±1°C using a cooling blanket, followed by rewarming at a speed 
of one degree per day.  
 
Blood Samples and Biochemical Markers 
Blood were sampled in all patients immediately after ICU admission, and were 
collected exactly at 6 and 24 hours after the time point of onset of CA (i.e., collapse of the 
patient in cases of witnessed CA or emergency call receipt in cases of non-witnessed CA). 
Sampled blood was centrifuged at 3000 rpm for 10 minutes. The isolated serum was 
immediately frozen at a temperature < -70°C and stored at the same temperature until it was 
assayed. The serum level of S-100B was determined by an immunoluminometric assay (clone 
8B10 and 6G1, HyTest Ltd, Turku, Finland) with a limit of detection of 0.05 ng/mL with an 
institutional normal of < 0.06 ng/mL, while that of NSE was determined by an 
immunoradiometric assay (ProlifigenR NSE IRMA, DiaSorin Inc., USA) with a limit of 
detection of 0.8 ng/mL with an institutional normal of < 10.6 ng/mL. 
 
Assessment of outcomes 
The cerebral performance of individual patients was evaluated using 
Glasgow-Pittsburgh Cerebral Performance Categories (CPC)[8] (categories 1-5), and the 
"best-ever achieved" CPC was recorded during the hospital stay for all patients, as 
recommended by the Utstein templates[7]. In the present investigation, the "best-ever 
achieved" CPC within 6 months from the onset of CA in cases "discharged alive" and that for 
the period between onset of CA and in-hospital death in cases "discharged dead" was defined 
as the patient's neurological outcome. The patients were then classified into two groups on 
the basis of neurological outcome: the "poor neurological outcome" group (CPC3 to CPC5) 
and the "favorable neurological outcome" group (CPC1 and CPC2). 
 
Statistical Analysis 
Values are given as means and standard deviations (SD) for parametric values and 
as medians and inter-quartile ranges for nonparametric values unless otherwise specified. 
S-100B and NSE levels in poor and favorable neurological outcome groups were compared 
by repeated-measures analysis of variance (ANOVA) after logarithmic transformation. 
Scheffe's test was used as a post hoc test. c2 test or Fisher's exact test was used to compare 
proportions. Continuous data were compared with the unpaired t-test or the Mann-Whitney U 
test, as appropriate. A two-tailed P value of < 0.05 was considered statistically significant. 
The discriminative power of S-100B and NSE in predicting poor outcome was evaluated by 
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receiver-operating characteristics (ROC) analysis. All statistical analyses were carried out 
using SPSS software (SPSS Japan Inc.).  
  
Subgroup Analysis 
 S-100B and NSE values are known to elevate in patients who have brain 
damages[11]. Therefore, we performed subgroup analysis that restricts the patients to cardiac 
etiology with the exception of neurological factors that might be thought to release more 
S-100B and NSE into the blood of patients. The subjects of the present study were divided 
into two groups based on their etiology; cardiac etiology and the other. In the cardiac etiology 
group, the mean value of S-100B and NSE were compared between the poor neurological 
outcome group and the favorable neurological outcome group. ROC analysis was performed 
for the evaluation of the discriminative power of S-100B and NSE in predicting poor 
outcome in the same manner. 
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Results 
Eligible patients 
During the study period, a total of 111 eligible patients (68 men and 43 women; 
mean age, 67±14 years; range, 24-94 years) were admitted (Figure 1). Twenty-four of them 
were excluded from the study for the reasons shown in Figure 1. The remaining 87 patients 
were included in the study, though one patient dropped out due to transfer to another hospital 
prior to the initial blood sampling. The median time interval from CA to the initial blood 
sampling was 128 minutes (inter-quartile range, 78-181 minutes). As a result of dropping out 
from the study by patients due to transfer to another hospital, death, or the failure of study 
collaborators to collect blood samples, the numbers of blood samples obtained at the initial, 
second, and third samplings were 83, 77, and 62, respectively. With further exclusion of two 
patients who met the exit criterion (failure to evaluate CPC due to death under analgesic 
sedation), the final numbers of patients subjected to assessment of biochemical markers at the 
initial, second, and third samplings were 81, 75, and 60, respectively.  
 
Outcome variables 
A total of 84 patients were assessed for neurological outcome without failure to 
determine the final outcome (Figure 1). The "favorable neurological outcome" group (n=13) 
included 11 patients evaluated as CPC1 and 2 patients as CPC2. The "poor neurological 
outcome" group (n=71) included eight patients evaluated as CPC3, 34 patients as CPC4, and 
29 patients as CPC5. All patients in the "favorable neurological outcome" group were finally 
discharged alive to home. All patients evaluated as CPC3 were discharged to chronic-care 
facilities, and were either staying at the same facility or were dead at the time of the 
follow-up interview 6 months after CA, with none returning home.  
The baseline characteristics of the two groups with different neurological outcomes 
are compared in Table 1. 
 
Serum S-100B and NSE levels 
Figures 2 and 3 show changes over time in serum levels of S-100B and NSE, 
respectively. A significant decrease in serum S-100B with time was observed in the 
"favorable neurological outcome" (P<0.01) but not in the "poor neurological outcome" 
(Figure 2). The mean serum S-100B in the "poor neurological outcome" was significantly 
higher than that in the "favorable neurological outcome" at all of the three sampling time 
points. 
A significant increase in serum NSE with time was observed in the "poor 
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neurological outcome" (P<0.01) but not in the "favorable neurological outcome" (Figure 3). 
The mean serum NSE in the "poor neurological outcome" was significantly higher than that 
in the "favorable neurological outcome" at two of the three sampling time points: 6 hours and 
24 hours after CA. 
 Table 2 shows, in addition to the cutoff value predictive of a poor neurological 
outcome with a specificity of 100%, the value of sensitivity corresponding to this cutoff value 
and area under the ROC curve (AUC) for each of the six data sets. These findings 
demonstrated that both the AUC and sensitivity calculated for S-100B were consistently 
higher than those for NSE within 24 hours after CA. The “100%-specific” cutoff values for 
serum S-100B level predictive of poor neurological outcome on ICU admission and at 6 and 
24 hours after CA were 1.34 ng/mL, 0.20 ng/mL, and 0.05 ng/mL, respectively. 
  In the subgroup analysis that restricts the subject to cardiac etiology (n=41), the 
number of samples was 40 on admission, 38 at 6 hours after CA, and 34 at 24 hours after CA, 
respectively. Statistically significant difference was recognized between the "poor 
neurological outcome" group and "favorable neurological outcome" group at all of the three 
sampling time points for S-100B, whereas the difference was noted only at 24 hours after CA 
for NSE. With regard to S-100B, AUC was 0.847 [0.688-1.005] on admission, 0.932 
[0.840-1.024] at 6 hours after CA, and 1.00 [1.00-1.00] at 24 hours after CA. AUC for NSE 
was 0.642 [0.412-0.871], 0.679 [0.498-0.859], 0.847 [0.688-1.005], respectively. The 
“100%-specific” cutoff values for serum S-100B level predictive of poor neurological 
outcome on ICU admission and at 6 and 24 hours after CA were 1.36 ng/mL, 0.23 ng/mL, 
and 0.05 ng/mL, respectively. 
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Discussion 
 The present study demonstrated the superior reliability of S-100B within 24 hours 
after CA following CPR as a neurological prognostic predictor to that of NSE. S-100B, when 
presented at high levels, is considered a mediator involved in brain cell apoptosis that may 
play roles as a cytokine[12,13]. High serum S-100B levels suggest high local levels of 
S-100B in the brain[14]. Accordingly, in patients with a high serum S-100B level after CA 
and CPR, S-100B presented at high levels in the brain is supposed to act as a cytokine to 
induce extensive brain cell apoptosis leading to aggravation of post-resuscitative brain 
damage.  
NSE is a protein located in nerve cells and detectable in body fluids as a marker 
enzyme indicative of nerve cell damage[15]. Therefore, monitoring of serum NSE level 
focuses on cell death as a result of hypoxic brain damage. We confirmed in the present study 
an increase in serum NSE level over time in patients with poor neurological outcome and a 
decrease in serum S-100B level in those with favorable outcome (Figures 2, 3). These 
changes have been recognized in many preceding studies[9,16-21], and ascribed to the 
difference in biological half-life between these two proteins. However, these changes can also 
be explained by considering S-100B a cause of hypoxic brain damage and NSE an enzyme 
released from nerve cells to reflect a result of hypoxic brain damage. S-100B serves as a 
prognostic predictor within 24 hours after CA and thus at an earlier stage than other factors 
(including NSE), which focus on the consequences of hypoxic brain damage and are 
therefore meaningful as prognostic predictors one to three days after CA[1].  
Böttiger et al[22]. demonstrated that the serum S-100B level in post-resuscitative 
brain damage varied every hour. This finding indicates that, in assessment of the clinical 
value of S-100B, the time points of blood sampling must be specified as at certain time 
intervals starting from a clearly definable time point, and that blood samples must be 
collected from all patients at exactly the same time point.  
We collected blood samples at definite time intervals (6 and 24 hours) starting from 
the time point of onset of CA (i.e., collapse of the patient) as witnessed or emergency call 
receipt for the patient in cases of non-witnessed CA. In cases of non-witnessed CA, the time 
point of emergency call receipt was used to approximate the time point of actual onset of CA. 
Using time points clearly definable in both witnessed and non-witnessed cases (such as time 
of CPR initiation, arrival at hospital, ROSC, and hospital admission)[17,18,22-25] might 
result in even greater deviation from the actual time point of onset of CA due to inclusion of 
intervals including driving of an emergency response vehicle to the scene, transfer to the 
hospital, and treatment in the hospital.  
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A study design involving repeated blood sampling in identical patients and focused 
on the interval of each sampling from a certain starting point had previously been adopted 
only by Tiainen et al[18]. starting from ROSC and Böttiger et al[22]. starting from CPR 
initiation. 
To our knowledge, only Grubb et al[16]. reported a large study including more than 
100 subjects about the prognostic value of serum S-100B within 24 hours after CA. 
Summarizing the above, no large prospective observational study assessing the reliability of 
serum S-100B level within 24 hours after CA as a prognostic predictor of the neurological 
outcome of CA following CPR with use of the same blood sampling schedule for all patients 
included with the time point of blood sampling specified by interval from onset of CA as the 
starting point has been reported previously, and the present study is the first to do so.  
We sought cutoff values for serum S-100B and NSE predictive of poor neurological 
outcome with a specificity of 100% (Table 2). Since prediction of a poor prognosis is often 
needed for decisions regarding therapeutic measures to be taken for a particular patient, the 
false-positive rate for such prediction should be 0% and, accordingly, specificity should be 
100%[20]. 
The cutoff value for S-100B obtained in the present study was compared with those 
reported previously. Cutoff values calculated for an identical prognostic predictor in different 
studies cannot be compared without application of a common definition of outcome 
(endpoint). There are different definitions of outcome: (1) survive or death; (2) "presence" 
(CPC1, 2, 3) or "absence" (CPC4, 5) of regaining of consciousness; and (3) "with (CPC1, 2)” 
or “without (CPC3, 4, 5)” return to normal social activity. The difference between definitions 
(2) and (3) is particularly important, since inclusion of patients categorized as CPC3 in the 
"poor outcome" group depends on selection between these two alternative definitions.  
Of the 12 previous studies on the clinical usefulness of S-100B as a prognostic 
predictor of the outcome of CA following CPR[9,16-19,22-29], three[18,19,24] adopted 
definition (3). We adopted definition (3), because the final goal of emergency medical care in 
CA is regaining normal activities of daily living[30,31] and a prognostic predictor 
discriminating with or without return to normal social activity can be expected to be of 
greatest use in clinical practice.  
Among the three studies to be compared with ours, Tiainen et al[18]. assessed the 
reliability of serum S-100B sampled at 24, 36, and 48 hours after ROSC in two treatment 
groups, the "hypothermia" and the "normothermia". They reported that the cutoff value of 
serum S-100B with a specificity of 100% corresponding to the highest value of sensitivity 
was 0.21 ng/mL at 24 hours in the "hypothermia" group and 0.12 ng/mL at 48 hours in the 
 
- 9 - 
"normothermia" group (sensitivity 30% and 80%, respectively). Mussack et al[24]. collected 
blood samples only once at a mean interval of 12.5 hours after ROSC and reported a cutoff 
value of 0.76 ng/mL (specificity, 100%; sensitivity, 54%). Rosen et al[19]. collected blood 
samples three times, at mean "post-arrest" intervals of 10.5, 35.8, and 60.0 hours and reported 
that a cutoff value of 0.217 ng/mL measured at 35.8 hours corresponded to a positive 
predictive value of 100% and a highest negative predictive value of 58%.  
The cutoff values for serum S-100B determined in the present study were 0.20 
ng/mL and 0.05 ng/mL (6 and 24 hours after CA, respectively) (Table 2), and considerably 
lower than those previously reported. This difference may have been due to differences in the 
method of assay employed.  
 S-100 was shown to constitute a homo or heterodimer of two distinct but related 
proteins: S-100A and S-100B with a molecular weight of approximately 9-13 kDa, 
respectively. Heizmann[32] showed that the widely used two-site immunoassay (Sangtec 100 
IRMA) from DiaSorin AB (Bromma, Sweden) was specific and reliable for measurement of 
S-100B. Our method by an immunoluminometric assay (clone 8B10 and 6G1, HyTest Ltd, 
Turku, Finland) is also specific for S-100B that has only 0.1% of cross-reactivity to S100A. 
However, there was a difference between our cutoff values and other’s that were assayed by 
the widely used methods. The reason is thought to be a difference of the antibodies and the 
assay procedure. In fact, the sensitivity of the assay by Sangtec 100 IRMA is 0.2 ng/mL, 
whereas the sensitivity of our method is 0.05 ng/mL. Therefore, it is difficult to compare the 
cutoff values indiscriminately.  
The assay time employed in this study is 5-6 hours. Because our method needs to 
fix the capture antibody to 1×96 microtiter wells before starting reaction, we needs 2-3 
hours more than the widely used methods. Prognostic biomarkers for neurological deficit 
should be assayed as quickly as possible. It is ideal for the assays those have required time 
within one hour, and are completed at bedside. Further improvement of the assay method, for 
example a chemiluminescent enzyme immunoassay, is required to refer to the usefulness of 
S100B as a prognostic biomarker. 
The present study has a limitation that is related to effects of concomitant therapy. 
Hypothermic therapy for prevention of hypoxic brain damage is known to lower serum levels 
of biochemical markers such as S-100B and NSE[18,28]. In the present study, the decision to 
perform hypothermia therapy was left to each physician treating each included patient, since 
we could not establish clear and definite criteria for use of this therapy to be applied to the 
study subjects. The decision to perform therapeutic hypothermia in a patient who has no 
family or proxy to provide consent to it is very difficult for a critical care physician in Japan, 
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considering many factors. On the other hand, the healthcare provider is not allowed to reject a 
particular therapy if the patient's family insists upon it. Considering these social, ethical, and 
medical problems, it is currently impossible in Japan to adopt a study design involving 
therapeutic hypothermia therapy with clear criteria for use of it in assessment of outcome in 
CA. The design employed in the present study matches actual clinical practice and it is 
therefore our belief that the conclusions derived from the present study will be more useful 
and applicable to the clinical situation compared than those obtained with use of a different 
design, like that by Tiainen et al[18]. 
 Excluding neurological factors that might affect the blood levels of S-100B and 
NSE, we performed subgroup analysis that restricts the patients to cardiac etiology. The 
results from the subgroup analysis were almost the same conclusion as S-100B was more 
reliable than NSE as an early predictor of poor neurological outcome within 24 hours after 
CA following CPR. 
S-100B has been extensively studied as a mediator and/or a prognostic predictor and utilized 
as a determinant of therapeutic effects in a variety of fields[33-35]. The variety of roles of 
S-100B as a prognostic predictor in CA, a cause of brain damage, and a determinant of 
effects of cerebroprotective therapies await further investigation.  
 As a conclusion, S-100B was more reliable as an early predictor of poor 
neurological outcome within 24 hours after CA following CPR than NSE and can be applied 
clinically. 
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Table 1. Baseline characteristics of patients with poor and favorable neurological outcomes 
 All patients 
n=84 
Patients with poor neurological outcome 
n=71 
Patients with favorable neurological outcome 
n=13 
P-Value 
Age (years) 66±15 67±15 59±12 0.063 
Male gender, n(%) 52(62) 39(55) 13(100) 0.001 
OHCA, n(%) 64(76) 52(73) 12(92) 0.180 
Cardiac origin, n(%) 41(49) 31(44) 10(77) 0.036 
Witnessed CA, n(%) 63(75) 50(70) 13(100) 0.032 
First ECG as shockable, 
n(%) 
17(20) 8(11) 9(69) <0.001 
BLS within 5min, n(%) 28(33) 20(28) 8(62) 0.027 
Therapeutic hypothermia, 
n(%) 
48(57) 38(54) 10(77) 0.139 
Values are expressed as numbers, percentages, means ±SD. 
OHCA indicates out-of-hospital cardiac arrest; CA, cardiac arrest; ECG, electrocardiogram; 
BLS, basic life support; Shockable rhythms were defined as ECG showing ventricular 
fibrillation or pulseless ventricular tachycardia 
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Table 2. AUC values and cut-off values with 100% specificity in predicting poor 
neurological outcome for serum S-100B and NSE 
 Cut-off value 
(ng/mL) 
Specificity 
(%) 
Sensitivity 
(%) 
AUC [95%CI] 
S-100B     
On admission (n=81) 1.34 100 33.8 0.881 [0.770-0.991] 
6 hours after CA (n=75) 0.20 100 72.6 0.958 [0.910-1.007] 
24 hours after CA (n=60) 0.05 100 100 1.000 [1.000-1.000] 
NSE     
On admission (n=81) 45.6 100 8.8 0.670 [0.475-0.864] 
6 hours after CA (n=75) 66.3 100 27.4 0.759 [0.626-0.893] 
24 hours after CA (n=60) 39.8 100 74.5 0.902 [0.825-0.979] 
CA indicates cardiac arrest; AUC, area under ROC curve; CI, confidence interval. 
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Figure legends 
Figure 1. Overview of patient enrollment 
Exclusion criteria: 1) a terminal condition with known unfavorable cerebral performance 
(CPC3-4) before CA; or 2) response to verbal commands after ROSC.  
Exit criterion: impossibility to evaluate CPC due to death of the patient under analgesic 
sedation. 
CA indicates cardiac arrest; OHCA, out-of-hospital cardiac arrest; IC, informed consent; CPC, 
the Glasgow-Pittsburgh cerebral performance categories 
 
Figure 2. Time course of serum S-100B levels within 24 hours after CA in patients with 
favorable and poor neurological outcomes  
Error bars indicate mean ±SD values.  
CA indicates cardiac arrest; CPC, the Glasgow-Pittsburgh cerebral performance categories. 
 
 
Figure 3. Time course of serum NSE levels within 24 hours after CA in patients with 
favorable and poor neurological outcomes.  
Error bars indicate mean ±SD values.  
CA indicates cardiac arrest; CPC, the Glasgow-Pittsburgh cerebral performance categories. 
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